In summary, upregulating CAV-1 expression, reducing GSK-3β activity, and inhibiting excessive abnormal phosphorylation of Tau protein may be one of the molecular mechanisms of RSBFL for the prevention and treatment of AD. The gene discussed is GSK3B; the disease is Alzheimer disease.